CL2012001035A1 - Oral pharmaceutical composition comprising at least one progestagen and a folate derivative, antioxidants and an anti-humidity coating; use of the composition in contraception. - Google Patents

Oral pharmaceutical composition comprising at least one progestagen and a folate derivative, antioxidants and an anti-humidity coating; use of the composition in contraception.

Info

Publication number
CL2012001035A1
CL2012001035A1 CL2012001035A CL2012001035A CL2012001035A1 CL 2012001035 A1 CL2012001035 A1 CL 2012001035A1 CL 2012001035 A CL2012001035 A CL 2012001035A CL 2012001035 A CL2012001035 A CL 2012001035A CL 2012001035 A1 CL2012001035 A1 CL 2012001035A1
Authority
CL
Chile
Prior art keywords
composition
contraception
antioxidants
progestagen
oral pharmaceutical
Prior art date
Application number
CL2012001035A
Other languages
Spanish (es)
Inventor
Del Transito Gamboa Arancibia Rodrigo Ivan Ramirez Monetta Alexander
Original Assignee
Igloo Zone Chile S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igloo Zone Chile S A filed Critical Igloo Zone Chile S A
Priority to CL2012001035A priority Critical patent/CL2012001035A1/en
Publication of CL2012001035A1 publication Critical patent/CL2012001035A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica oral que comprende al menos un progestágeno y un derivado de folato, antioxidantes y un recubrimiento antihumedad; uso de la composición en la contracepción.Oral pharmaceutical composition comprising at least one progestogen and a folate derivative, antioxidants and an anti-humidity coating; use of the composition in contraception.

CL2012001035A 2012-04-24 2012-04-24 Oral pharmaceutical composition comprising at least one progestagen and a folate derivative, antioxidants and an anti-humidity coating; use of the composition in contraception. CL2012001035A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2012001035A CL2012001035A1 (en) 2012-04-24 2012-04-24 Oral pharmaceutical composition comprising at least one progestagen and a folate derivative, antioxidants and an anti-humidity coating; use of the composition in contraception.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2012001035A CL2012001035A1 (en) 2012-04-24 2012-04-24 Oral pharmaceutical composition comprising at least one progestagen and a folate derivative, antioxidants and an anti-humidity coating; use of the composition in contraception.

Publications (1)

Publication Number Publication Date
CL2012001035A1 true CL2012001035A1 (en) 2012-07-13

Family

ID=69590303

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001035A CL2012001035A1 (en) 2012-04-24 2012-04-24 Oral pharmaceutical composition comprising at least one progestagen and a folate derivative, antioxidants and an anti-humidity coating; use of the composition in contraception.

Country Status (1)

Country Link
CL (1) CL2012001035A1 (en)

Similar Documents

Publication Publication Date Title
ECSP21072161A (en) LINACLOTIDE DELAYED RELEASE COMPOSITIONS
NZ712350A (en) Abiraterone acetate formulation
TR201908596T4 (en) Spiro-lactam NMDA receptor modulators and their uses.
MX2015009105A (en) Solid solution compositions and use in chronic inflammation.
EP2569330A4 (en) Chlorotoxin variants, conjugates, and methods for their use
MX2016001424A (en) Sweetener compositions.
TR201903569T4 (en) A delayed release drug formulation.
CL2012003075A1 (en) Pharmaceutical composition in pazopanib solution, stable and for ophthalmic use; method for the preparation of said solution.
BR112015018095A2 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX366317B (en) Compositions and methods for treating chronic inflammation and inflammatory diseases.
CO2019008103A2 (en) Pharmaceutical compositions for combination therapy
CO2017002472A2 (en) Abiraterone acetate formulation
BR112018002983A2 (en) composition comprising a lactam and an alcohol
NI201200157A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING HYDROMORPHONE AND NALOXONE
UY34730A (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE CCR3 ANTAGONISTS
AU2016289474B2 (en) HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents
CL2017000587A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
CL2013000069A1 (en) Compounds derived from fused heterocycles, s1p modulators; pharmaceutical composition; and use in neurodegenerative diseases.
BR112014025416A2 (en) ANTIMALARIC AGENTS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THEM AND USE OF THE SAME.
BR112013023575A2 (en) “octahydrothienoquinoline derivative, pharmaceutical composition comprising the derivative, and use thereof”
NI201000212A (en) DRONEDARONE FOR THE PREVENTION OF CARDIOVERSION.
IL238851A0 (en) Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
CY1118277T1 (en) STABLE PHARMACEUTICAL FORM PEXIGANANIS
HRP20130082A2 (en) Pharmaceutical composition with sustained release of trimetazidine
CL2015000610A1 (en) Isoxazolidine derivatives